(Q87702640)

English

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

scientific article published on 14 April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

based on heuristic

inferred from title

phase III clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Claudine Isaacs

10

object named as

Claudine Isaacs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

2

object named as

Ruth O'Regan

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Norikazu Masuda

7

object named as

Norikazu Masuda

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

4

object named as

Masakazu Toi

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Mustafa Ozguroglu

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Binghe Xu

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Guy Jerusalem

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Sharon Wilks

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Zsuzsanna Papai

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Istvan Lang

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Anne Armstrong

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Guillermo Lerzo

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Michelle White

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Kunwei Shen

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Jennifer Litton

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

David Chen

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Yufen Zhang

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Shyanne Ali

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Tetiana Taran

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

14 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

580-591

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast cancer--loss of PTEN predicts resistance to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70138-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24742739%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q87702640&oldid=2125678082"